2022-03-012023-02-282023-02-28false06502683CHELSEA HEALTHCARE LTD2023-11-2282990iso4217:GBPxbrli:pure065026832022-03-01065026832023-02-28065026832022-03-012023-02-28065026832021-03-01065026832022-02-28065026832021-03-012022-02-2806502683bus:SmallEntities2022-03-012023-02-2806502683bus:AuditExempt-NoAccountantsReport2022-03-012023-02-2806502683bus:FullAccounts2022-03-012023-02-2806502683bus:PrivateLimitedCompanyLtd2022-03-012023-02-2806502683core:WithinOneYear2023-02-2806502683core:AfterOneYear2023-02-2806502683core:WithinOneYear2022-02-2806502683core:AfterOneYear2022-02-2806502683core:ShareCapital2023-02-2806502683core:SharePremium2023-02-2806502683core:RevaluationReserve2023-02-2806502683core:OtherReservesSubtotal2023-02-2806502683core:RetainedEarningsAccumulatedLosses2023-02-2806502683core:ShareCapital2022-02-2806502683core:SharePremium2022-02-2806502683core:RevaluationReserve2022-02-2806502683core:OtherReservesSubtotal2022-02-2806502683core:RetainedEarningsAccumulatedLosses2022-02-2806502683core:LandBuildings2023-02-2806502683core:PlantMachinery2023-02-2806502683core:Vehicles2023-02-2806502683core:FurnitureFittings2023-02-2806502683core:OfficeEquipment2023-02-2806502683core:NetGoodwill2023-02-2806502683core:IntangibleAssetsOtherThanGoodwill2023-02-2806502683core:ListedExchangeTraded2023-02-2806502683core:UnlistedNon-exchangeTraded2023-02-2806502683core:LandBuildings2022-02-2806502683core:PlantMachinery2022-02-2806502683core:Vehicles2022-02-2806502683core:FurnitureFittings2022-02-2806502683core:OfficeEquipment2022-02-2806502683core:NetGoodwill2022-02-2806502683core:IntangibleAssetsOtherThanGoodwill2022-02-2806502683core:ListedExchangeTraded2022-02-2806502683core:UnlistedNon-exchangeTraded2022-02-2806502683core:LandBuildings2022-03-012023-02-2806502683core:PlantMachinery2022-03-012023-02-2806502683core:Vehicles2022-03-012023-02-2806502683core:FurnitureFittings2022-03-012023-02-2806502683core:OfficeEquipment2022-03-012023-02-2806502683core:NetGoodwill2022-03-012023-02-2806502683core:IntangibleAssetsOtherThanGoodwill2022-03-012023-02-2806502683core:ListedExchangeTraded2022-03-012023-02-2806502683core:UnlistedNon-exchangeTraded2022-03-012023-02-2806502683core:MoreThanFiveYears2022-03-012023-02-2806502683core:Non-currentFinancialInstruments2023-02-2806502683core:Non-currentFinancialInstruments2022-02-2806502683dpl:CostSales2022-03-012023-02-2806502683dpl:DistributionCosts2022-03-012023-02-2806502683core:LandBuildings2022-03-012023-02-2806502683core:PlantMachinery2022-03-012023-02-2806502683core:Vehicles2022-03-012023-02-2806502683core:FurnitureFittings2022-03-012023-02-2806502683core:OfficeEquipment2022-03-012023-02-2806502683dpl:AdministrativeExpenses2022-03-012023-02-2806502683core:NetGoodwill2022-03-012023-02-2806502683core:IntangibleAssetsOtherThanGoodwill2022-03-012023-02-2806502683dpl:GroupUndertakings2022-03-012023-02-2806502683dpl:ParticipatingInterests2022-03-012023-02-2806502683dpl:GroupUndertakingscore:ListedExchangeTraded2022-03-012023-02-2806502683core:ListedExchangeTraded2022-03-012023-02-2806502683dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-03-012023-02-2806502683core:UnlistedNon-exchangeTraded2022-03-012023-02-2806502683dpl:CostSales2021-03-012022-02-2806502683dpl:DistributionCosts2021-03-012022-02-2806502683core:LandBuildings2021-03-012022-02-2806502683core:PlantMachinery2021-03-012022-02-2806502683core:Vehicles2021-03-012022-02-2806502683core:FurnitureFittings2021-03-012022-02-2806502683core:OfficeEquipment2021-03-012022-02-2806502683dpl:AdministrativeExpenses2021-03-012022-02-2806502683core:NetGoodwill2021-03-012022-02-2806502683core:IntangibleAssetsOtherThanGoodwill2021-03-012022-02-2806502683dpl:GroupUndertakings2021-03-012022-02-2806502683dpl:ParticipatingInterests2021-03-012022-02-2806502683dpl:GroupUndertakingscore:ListedExchangeTraded2021-03-012022-02-2806502683core:ListedExchangeTraded2021-03-012022-02-2806502683dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-03-012022-02-2806502683core:UnlistedNon-exchangeTraded2021-03-012022-02-2806502683core:NetGoodwill2023-02-2806502683core:IntangibleAssetsOtherThanGoodwill2023-02-2806502683core:LandBuildings2023-02-2806502683core:PlantMachinery2023-02-2806502683core:Vehicles2023-02-2806502683core:FurnitureFittings2023-02-2806502683core:OfficeEquipment2023-02-2806502683core:AfterOneYear2023-02-2806502683core:WithinOneYear2023-02-2806502683core:ListedExchangeTraded2023-02-2806502683core:UnlistedNon-exchangeTraded2023-02-2806502683core:ShareCapital2023-02-2806502683core:SharePremium2023-02-2806502683core:RevaluationReserve2023-02-2806502683core:OtherReservesSubtotal2023-02-2806502683core:RetainedEarningsAccumulatedLosses2023-02-2806502683core:NetGoodwill2022-02-2806502683core:IntangibleAssetsOtherThanGoodwill2022-02-2806502683core:LandBuildings2022-02-2806502683core:PlantMachinery2022-02-2806502683core:Vehicles2022-02-2806502683core:FurnitureFittings2022-02-2806502683core:OfficeEquipment2022-02-2806502683core:AfterOneYear2022-02-2806502683core:WithinOneYear2022-02-2806502683core:ListedExchangeTraded2022-02-2806502683core:UnlistedNon-exchangeTraded2022-02-2806502683core:ShareCapital2022-02-2806502683core:SharePremium2022-02-2806502683core:RevaluationReserve2022-02-2806502683core:OtherReservesSubtotal2022-02-2806502683core:RetainedEarningsAccumulatedLosses2022-02-2806502683core:NetGoodwill2021-03-0106502683core:IntangibleAssetsOtherThanGoodwill2021-03-0106502683core:LandBuildings2021-03-0106502683core:PlantMachinery2021-03-0106502683core:Vehicles2021-03-0106502683core:FurnitureFittings2021-03-0106502683core:OfficeEquipment2021-03-0106502683core:AfterOneYear2021-03-0106502683core:WithinOneYear2021-03-0106502683core:ListedExchangeTraded2021-03-0106502683core:UnlistedNon-exchangeTraded2021-03-0106502683core:ShareCapital2021-03-0106502683core:SharePremium2021-03-0106502683core:RevaluationReserve2021-03-0106502683core:OtherReservesSubtotal2021-03-0106502683core:RetainedEarningsAccumulatedLosses2021-03-0106502683core:AfterOneYear2022-03-012023-02-2806502683core:WithinOneYear2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:CostValuation2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-012023-02-2806502683core:Non-currentFinancialInstrumentscore:CostValuation2023-02-2806502683core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-2806502683core:Non-currentFinancialInstrumentscore:CostValuation2022-02-2806502683core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-02-2806502683core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-02-2806502683bus:Director12022-03-012023-02-2806502683bus:Director22022-03-012023-02-2806502683core:FurnitureFittingsToolsEquipment2022-02-2806502683core:FurnitureFittingsToolsEquipment2023-02-2806502683core:FurnitureFittingsToolsEquipment2022-03-012023-02-28

CHELSEA HEALTHCARE LTD

Registered Number
06502683
(England and Wales)

Unaudited Financial Statements for the Year ended
28 February 2023

CHELSEA HEALTHCARE LTD
Company Information
for the year from 1 March 2022 to 28 February 2023

Directors

CHOHAN, Harjinder Singh
CHOHAN, Sundeep Singh, Dr.

Company Secretary

CHOHAN, Sundeep Singh, Dr.

Registered Address

260 - 270 Butterfield
Great Marlings
Luton
LU2 8DL

Registered Number

06502683 (England and Wales)
CHELSEA HEALTHCARE LTD
Balance Sheet as at
28 February 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets52,7663,255
Investment property6946,250915,000
949,016918,255
Current assets
Debtors102563,038
Cash at bank and on hand11,74345,284
11,99948,322
Creditors amounts falling due within one year11(10,043)(11,454)
Net current assets (liabilities)1,95636,868
Total assets less current liabilities950,972955,123
Creditors amounts falling due after one year12(116,716)(122,309)
Provisions for liabilities13(80,362)(80,362)
Accruals and deferred income(1,211)(1,229)
Net assets752,683751,223
Capital and reserves
Called up share capital100100
Revaluation reserve309,702309,702
Profit and loss account442,881441,421
Shareholders' funds8752,683751,223
The financial statements were approved and authorised for issue by the Board of Directors on 22 November 2023, and are signed on its behalf by:
CHOHAN, Sundeep Singh, Dr.
Director
Registered Company No. 06502683
CHELSEA HEALTHCARE LTD
Notes to the Financial Statements
for the year ended 28 February 2023

1.Statutory information
Chelsea Healthcare Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page. The presentation currency of the financial statements is the Pound Sterling (£).
2.Compliance with applicable reporting framework
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.
3.Accounting policies
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Fixtures and fittings15
Office Equipment33
Investment property policy
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.
Taxation policy
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current or deferred taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Foreign currency translation and operations policy
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
4.Employee information

20232022
Average number of employees during the year11
5.Property, plant and equipment

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 March 2210,42687411,300
At 28 February 2310,42687411,300
Depreciation and impairment
At 01 March 227,1718748,045
Charge for year489-489
At 28 February 237,6608748,534
Net book value
At 28 February 232,766-2,766
At 28 February 223,255-3,255
6.Investment property

£
Fair value at 01 March 22915,000
Additions31,250
At 28 February 23946,250
7.Dividends proposed and payable

2023

2022

££
Dividends Paid12,0002,000
Total12,0002,000
8.Movements in revaluation reserve

£
Reserve at 01 March 22309,702
At 28 February 23309,702
9.Further information regarding the company's income
Other operating income represents net rental income receivable, excluding value added tax.
10.Debtors

2023

2022

££
Other debtors-1,419
Prepayments and accrued income2211,619
Other debtors (Non-current)35-
Total2563,038
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
11.Creditors within one year

2023

2022

££
Trade creditors / trade payables-1,419
Bank borrowings and overdrafts5,8625,862
Taxation and social security1,630701
Other creditors2,5513,472
Total10,04311,454
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
12.Creditors after one year

2023

2022

££
Bank borrowings and overdrafts116,716122,309
Total116,716122,309
13.Provisions for liabilities

2023

2022

££
Net deferred tax liability (asset)80,36280,362
Total80,36280,362